<DOC>
	<DOCNO>NCT00977067</DOCNO>
	<brief_summary>The study consist two stage . In Stage 1 , maximum tolerate dose ( MTD ) determine . In Stage 2 , additional patient treat MTD GDC-0152 .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics GDC-0152 , Administered Intravenously Patients With Locally Advanced Metastatic Malignancies</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Histologically document , incurable , locally advanced metastatic solid malignancy , nonHodgkin 's lymphoma ( NHL ) without leukemic phase Disease ( either target nontarget lesion ) assess image study and/or physical examination For patient solid tumor NHL without leukemic phase , disease progression standard therapy , malignancy standard therapy All prior therapyrelated toxicity recover baselinegrade toxicity exception alopecia . Life expectancy ≥ 60 day Resting oxygen saturation ≥ 92 % room air Agreement use effective form contraception duration study Exclusion Criteria History central nervous system disease Chemotherapy , cancer hormonal therapy ( except GnRH agonist ) , radiotherapy , immunotherapy within 4 week prior Day 1 ( 6 week nitrosoureas mitomycin ) Use investigational agent device Major surgery significant traumatic injury within 3 week prior Day 1 Pregnant nursing Clinically significant cardiovascular disease , New York Heart Association ( NYHA ) Classification Grade 2 great congestive heart failure , ventricular arrhythmia require medication within 1 year prior Day 1 , NYHA Grade 2 great peripheral vascular disease Day 1 Known HIV infection Patients ongoing inflammatory process Grade ≥ 2 fever Grade ≥ 2 feverassociated constitutional symptom ( include rigors/chills , sweat , others determine investigator ) , clinically significant systemic infection within last month Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication History chronic liver disease , active hepatic infection , evidence hepatic cirrhosis , Grade ≥ 2 liver dysfunction . Baseline oxygen requirement history pulmonary fibrosis Any sign symptom Grade ≥ 2 National Cancer Institute Common Terminology Criteria Adverse Events , Version 3.0 , study entry except alopecia , pain , asymptomatic Grade 2 diffuse capacity lung carbon monoxide ( discretion investigator ) otherwise specify Patients need take concomitant medication , dietary supplement , food know inhibitor/inducer CYP3A4/5 and/or 2C8 metabolic pathway narrow therapeutic window involve enzyme metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>GDC0152</keyword>
	<keyword>IAP</keyword>
	<keyword>IAP Antagonist</keyword>
</DOC>